The Impact of Combretastatin A-4 on Cancer Cells and Circulating Tumor Cells (CTCs): A Multi-Assay Approach
Dimitrios Papakonstantinou, Vasileios Vardas, Despoina M. Varouhaki, Aikaterini Kotzamouratoglou, Karolina Mangani, Julia A. Ju, Catherine Alix-Panabières, Stuart S. Martin, Constantinos M. Athanassopoulos, Galatea Kallergi · 2026
Read The Impact of Combretastatin A-4 on Cancer Cells and Circulating Tumor Cells (CTCs): A Multi-Assay Approach by Dimitrios Papakonstantinou, Vasileios Vardas, Despoina M. Varouhaki, Aikaterini Kotzamouratoglou, Karolina Mangani, Julia A. Ju, Catherine Alix-Panabières, Stuart S. Martin, Constantinos M. Athanassopoulos, Galatea Kallergi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13591330.txt.
Description
Dimitrios Papakonstantinou and co-authors test a plant-derived drug on cancer cells in a 2026 study. Combretastatin A-4 breaks down the inner scaffolding of cells and has known anti-tumor action. The team asked how it changes spread-related traits, not just cell survival.
Four cell models were treated, from lung, breast, and colon cancers, plus a line grown from a colon patient's blood. Tests covered movement, colony growth, scaffold proteins, and tiny cell arms linked to spread. Doses ran for one and two days for comparison. A drug that also blunts the traits of wandering cells could slow metastasis. Blood-grown tumor cells make the test closer to real disease.
Catalog record
| CREATOR | Dimitrios Papakonstantinou, Vasileios Vardas, Despoina M. Varouhaki, Aikaterini Kotzamouratoglou, Karolina Mangani, Julia A. Ju, Catherine Alix-Panabières, Stuart S. Martin, Constantinos M. Athanassopoulos, Galatea Kallergi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |